Use of cucurbitacins for lung cancer research and therapy
- 6 April 2021
- journal article
- review article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 88 (1) , 1-14
Abstract
As the main substance in some traditional Chinese medicines, cucurbitacins have been used to treat hepatitis for decades in China. Currently, the use of cucurbitacins against cancer and other diseases has achieved towering popularity among researchers worldwide, as detailed in this review with summarized tables. Numerous studies have reported the potential tumor-killing activities of cucurbitacins in multiple aspects of human malignancies. Continuous research on its anticancer activity mechanisms also brings a glimmer of light to the treatment of patients with lung cancer. In line with the promising roles of cucurbitacins against cancer, through various molecular signaling pathways, it is justifiable to propose the use of cucurbitacins as a potential mainline chemotherapy before the onset and after the diagnosis of lung cancers. Here, this article mainly summarized the findings about the biological functions and underlying mechanisms of cucurbitacins on lung cancer pathogenesis and treatment. In addition, we also discussed the safety and efficacy of their application for further research and even clinical practice.Keywords
Funding Information
- National Natural Science Foundation of China (82002239)
- Natural Science Foundation of Hunan Province (2020JJ5934)
This publication has 130 references indexed in Scilit:
- Cucurbitacin covalent bonding to cysteine thiols: the filamentous-actin severing protein Cofilin1 as an exemplary targetCell Communication and Signaling, 2013
- ATP Mediates NADPH Oxidase/ROS Generation and COX-2/PGE2 Expression in A549 Cells: Role of P2 Receptor-Dependent STAT3 ActivationPLOS ONE, 2013
- Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasionBreast Cancer Research and Treatment, 2012
- Epidermal growth factor upregulates endometrial CYR61 expression via activation of the JAK2/STAT3 pathwayReproduction, Fertility and Development, 2011
- Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylationBritish Journal of Cancer, 2011
- Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer‐derived CD133‐positive cellsCancer, 2011
- Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetabilityDrug Delivery, 2010
- Cucurbitane-Type Triterpenoids from the Stems of Cucumis meloJournal of Natural Products, 2009
- Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumorsInternational Journal of Pharmaceutics, 2008
- Cucurbitane Triterpenes from the Fruiting Bodies and Cultivated Mycelia of Leucopaxillus gentianeusJournal of Natural Products, 2006